EU Approves Idelalisib
Idelalisib has been approved by the European Union for the treatment of patients with chronic lymphocytic leukaemia (CLL) and follicular lymphoma (FL). Idelalisib, an oral therapy, is an inhibitor of P13K delta, a protein that is overexpressed in many B-cell malignancies.
In patients with CLL, idelalisib can be used in conjunction with rituximab as a second-line treatment. In patients with FL, idelalisib can be given as monotherapy to those who are refractory to two prior lines of therapy. For more information, click here.